What is the current stock price of Anthera Pharmaceuticals, Inc. (ANTH)?

As of the latest market data, Anthera Pharmaceuticals, Inc. (ANTH) is trading at $0.00. The stock has seen a loss of 0.00% today.

Does Anthera Pharmaceuticals, Inc. (ANTH) pay a dividend?

Based on current data, Anthera Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Anthera Pharmaceuticals, Inc.?

The current market capitalization of Anthera Pharmaceuticals, Inc. (ANTH) is approximately unavailable.

ANTH

Anthera Pharmaceuticals, Inc.·Healthcare

0.00

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.00

ANTH NEWS

defenseworld.net

Mar 31

Anthera Pharmaceuticals (OTCMKTS:ANTH) Shares Cross Above Two Hundred Day Moving Average – What’s Next?

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.00 and traded as high as $0.0001. Anthera Pharmaceuticals shares last traded at $0.00, with a volume of 0 shares changing hands. Anthera Pharmaceuticals Trading Down 100.0%

defenseworld.net

Feb 21

Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH - Get Free Report) crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $0.00 and traded as high as $0.0001. Anthera Pharmaceuticals shares last traded at $0.00, with a volume of 0 shares. Anthera Pharmaceuticals Price Performance Anthera Pharmaceuticals

Company Profile

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2010-03-01

Beta

-123.12

Websitewww.anthera.com↗